ROS1 and non-small cell lung carcinoma: In August 2019, entrectinib received FDA approval for adult and pediatric patients ≥12 years with NTRK fusion-positive solid tumors and for ROS1-positive non-small cell lung cancer, representing a milestone in the adoption of molecularly guided cancer therapies.